Related Experiment Video
Updated: Aug 21, 2026
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Safety of the trivalent inactivated influenza vaccine among children: a population-based study
Eric K France1, Jason M Glanz, Stanley Xu
1Clinical Research Unit, Kaiser Permanente Colorado, Denver, USA. eric.k.france@kp.org
Insights
This study found no significant safety concerns for the inactivated trivalent influenza vaccine in children. Pediatric influenza vaccination is safe, with no increased medical visits observed post-immunization.
Area of Science:
- Pediatric medicine
- Vaccinology
- Public health
Background:
- Limited population-based safety data for inactivated trivalent influenza vaccine in children.
- Need for robust safety assessments in pediatric populations.
Purpose of the Study:
- To evaluate the safety of the inactivated trivalent influenza vaccine in a large pediatric population.
- To screen for increased medical visits within 2 weeks post-vaccination compared to control periods.
Main Methods:
- Self-controlled screening analysis of 251,600 children vaccinated between 1993-1999.
- Comparison of medical visit risks (outpatient, ED, inpatient) in the 14 days post-vaccination versus two control periods.
- Validation of significant findings through medical record review.
Main Results:
- Four diagnoses (impetigo, dermatitis, uncomplicated diabetes mellitus, ureteral disorder) showed potential association in initial screening.
- Medical record review confirmed impetigo in 6-23 month olds as significantly associated with vaccination (9 cases).
- No other significant medically attended events were linked to pediatric influenza vaccination.
Conclusions:
- This large-scale safety study found no evidence of significant medically attended events associated with pediatric influenza vaccination.
- The inactivated trivalent influenza vaccine demonstrates a favorable safety profile in children.
- Further research may focus on specific events like impetigo in younger age groups.
Background:
To our knowledge, there are no published population-based studies on the safety of the inactivated trivalent influenza vaccine among children.
Objective:
To screen a large population of children for evidence of increased medical visits in the 2 weeks after influenza vaccination compared with 2 control periods. Secondary analyses included shorter risk periods and restricted age categories.
Design:
Self-control screening analysis. Children vaccinated from January 1, 1993, through December 31, 1999, were randomly divided into 2 equal groups. In group 1, risks of outpatient, emergency department, and inpatient visits during the 14 days after vaccination were compared with the risks of visits in 2 control periods. Significant plausible medically attended events identified in group 1 were then analyzed in group 2, using the same 2 control periods. Medically attended events significant in both groups were considered potentially associated with vaccination and were assessed by medical record review.
Setting:
Five managed care organizations in the United States.
Participants:
Children younger than 18 years who received an influenza vaccination in one of the managed care settings (N = 251 600).
Main Outcome Measure:
Among vaccinated children seen for a medically attended event, the odds of the visit occurring in the 2 weeks after vaccination vs during 1 of the 2 control periods.
Results:
Study participants incurred 1165, 230, and 489 different diagnoses during the 14 days after vaccination according to the outpatient, emergency department, and inpatient data, respectively. Four diagnoses were positively associated with the vaccine in both groups 1 and 2: impetigo, dermatitis, uncomplicated diabetes mellitus, and ureteral disorder not otherwise specified. After medical record review, impetigo (9 cases) in children 6 to 23 months old remained significantly associated with vaccination.
Conclusion:
This large screening safety study did not reveal any evidence of important medically attended events associated with pediatric influenza vaccination.
Related Concept Videos
01:51Vaccinations
01:27Influenza
01:29Drug Dosing: Infants and Children
01:29Respiratory Syncytial Virus Disease